What people are saying.

July 31, 2017

Kite Files the Industry’s First CAR-T Marketing Authorization Application in Europe for Axicabtagene Ciloleucel

July 26, 2017

Sienna Biopharmaceuticals, Inc. Announces Pricing of Initial Public Offering of Common Stock

July 20, 2017

Kite Highlights Durable Complete Remissions Up to 56+ Months in Patients with Chemorefractory Aggressive Non-Hodgkin Lymphoma (NHL) after Anti-CD19 CAR T-Cell Therapy at the National Cancer Institute

July 19, 2017

Investigational New Drug Application for RTGel™ in Combination with BOTOX® for the Treatment of Overactive Bladder Submitted to FDA by Allergan

July 18, 2017

Capricor Receives Rare Pediatric Disease Designation from FDA for CAP-1002 for Patients with Duchenne Muscular Dystrophy

June 27, 2017

Kite Named to the MIT Technology Review’s Annual 50 Smartest Companies List in Recognition for its Leadership in Establishing CAR-T Therapy

June 14, 2017

Sienna Biopharmaceuticals Appoints Erle Mast, Former CFO and Co-Founder of Clovis Oncology, to Board of Directors

June 7, 2017

Cell Design Labs Announces Issuance of Broad Patent for Chimeric Notch Receptor to Treat Cancer and other Diseases

June 5, 2017

Kite Reports 73 Percent of Patients Achieved MRD Negative Complete Remission in Updated Analysis From Phase 1 ZUMA-3 CAR-T Trial of KTE-C19 in Adult Patients With High Burden Relapsed/Refractory Acute Lymphoblastic Leukemia

May 26, 2017

Kite Receives U.S. Food and Drug Administration Priority Review for Axicabtagene Ciloleucel

May 16, 2017

UroGen Pharma Appoints Fred E. Cohen, MD, to its Board of Directors

May 10, 2017

UroGen Pharma Announces Closing of Initial Public Offering and Exercise of Underwriters’ Option

May 8, 2017

Capricor Therapeutics Announces Private Placement of Common Stock

April 25, 2017

Capricor Therapeutics Announces Positive Six-Month Results from the Randomized Phase I/II HOPE Clinical Trial in Duchenne Muscular Dystrophy

April 24, 2017

UroGen Pharma Welcomes New Board Member Kate Falberg

April 24, 2017

Sienna Biopharmaceuticals Announces $40 Million Series B Financing

April 6, 2017

Kite Wins ‘Clinical Trial Result of the Year’ for its Pivotal CAR-T Trial of Axicabtagene Ciloleucel in Patients with Aggressive Non-Hodgkin Lymphoma at the 2017 Clinical and Research Excellence Awards

April 3, 2017

UroGen Pharma Announces Enrollment of First Patient in Phase 3 Clinical Trial of MitoGel™ for Treatment of Low-Grade Upper Tract Urothelial Carcinoma

April 2, 2017

Kite Presents Ongoing Response Rate in Plenary Session from its Pivotal CAR-T Trial of Axicabtagene Ciloleucel in Patients with Aggressive Non-Hodgkin Lymphoma at the 2017 American Association of Cancer Research Annual Meeting

March 31, 2017

New Gene Therapy for Cancer Offers Hope to Those With No Options Left

March 31, 2017

Kite Completes Submission of U.S. Biologics License Application (BLA) for Axicabtagene Ciloleucel as the First CAR-T Therapy for the Treatment of Patients With Aggressive Non-Hodgkin Lymphoma (NHL)

March 24, 2017

Richard Peterson Joins Sienna Biopharmaceuticals As Chief Financial Officer

March 20, 2017

Hubble Contacts Wants To Do For Contact Lenses What Harry’s Did For Razors

March 15, 2017

Cell Design Labs Announces Issuance of a Broad Patent for Programmable CAR-T Cells to Treat Cancer and Other Diseases

March 14, 2017

Kite Pharma Highlights Publication from the National Cancer Institute Demonstrating Durable Complete Remissions in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma Following Low Dose Conditioning Chemotherapy and Anti-CD19 CAR T-Cell Therapy